STAT+: Omada tackles obesity drugs, Boston Scientific nixes deal, and Microsoft health exec on GPT

You’re reading the web edition of STAT Health Tech, our guide to how tech is transforming the life sciences. Sign up to get this newsletter delivered in your inbox every Tuesday and Thursday. 

Omada Health announced it will launch a new service to help employers respond to the soaring demand for expensive GLP-1 weight loss treatments like Wegovy. When employees of participating companies seek to have their treatments covered by health plans, they’ll be asked to join Omada’s program that encourages lifestyle changes that might help people keep weight off.

Omada, which offers a host of virtual chronic disease management programs that focus on behavior change, won’t actually write or fill prescriptions for the drugs, a service that CEO Sean Duffy told STAT has been commoditized to the point that people don’t need more options.

Continue to STAT+ to read the full story…